Abstract
177Lu-PSMA radioligand therapy (RLT) using inhibitors of the prostate-specific membrane antigen (PSMA) is a novel therapeutic option in patients with metastatic castration-resistant prostate cancer (mCRPC). Current literature suggests that this therapy is well tolerated and effective. Based on clinical need and current evidence it is implemented in a growing number of centers worldwide. Here we review important aspects of 177Lu-PSMA RLT, including patient stratification, therapy protocol, concomitant medication and follow-up to inform medical staff involved in RLT and care of mCRPC patients.
- Copyright © 2017 by the Society of Nuclear Medicine and Molecular Imaging, Inc.